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Abstract: Purpose: There is little published data on the optimal energy to use to minimize doses to Organs at Risk 
(OARs), while maintaining adequate Planning Target Volume (PTV) coverage in lung volumetric-modulated arc therapy 
(VMAT) stereotactic body radiation therapy (SBRT). 
Methods: 35 lung lesions in 33 patients were treated at our institution by VMAT SBRT. Dosimetric plans using 6-
Megavoltage (6-MV) and 10-Megavoltage (10-MV) energies were generated for each lesion. The median dose was 
5000cGy delivered over 3-5 daily fractions. Various dosimetric parameters were recorded for both the 6-MV and 10-MV 
plans and the patients were stratified according to the tumor to chest wall distance (TCW), the tumor location (central 
versus peripheral), patient anterior-posterior (AP) diameter, and the diameter of an equivalent sphere encompassing the 
patient's body over the distance of the PTV (ESD). 
Results: There was a statistically significant difference between 6-MV and 10-MV with respect to the sum lung dose, 
which favored 6-MV plans (p=0.04). For those stratified by TCW, there was a difference in conformity index (CI) for 
patients with peripheral tumors (p=0.04). For the group stratified by AP separation, there was a difference in mean sum 
lung dose favoring 6-MV (p=0.01). In the group stratified by ESD, there were statistically significant (SS) differences in 
the volume of lung receiving at least 13Gy (V13), mean sum lung dose, and CI, all favoring 6-MV plans (p=0.05, p<0.01, 
and p<0.01). For the cohort overall, and within each subgroup, there was a SS difference in the total number of monitor 
units (MUs), which consistently favored planning with 10-MV.  
Conclusion: With the exception of thinner patients, for which 6-MV plans was superior with respect to OARs and 
conformity index, 10-MV should be considered for use in lung VMAT SBRT. 10-MV plans consistently resulted in fewer 
total MUs. Fewer MUs results in shorter treatment times, with the potential for improved target accuracy due to less 
intrafractional tumor motion.  
Keywords: Stereotactic body radiation therapy, Lung cancer, Volumetric-modulated arc therapy, Physics, intensity 
modulated radiation therapy. 
INTRODUCTION 
Lung cancer is the leading cause of cancer-related 
mortality in the United States and worldwide [1]. About 
80% of all lung cancers are non-small cell lung cancer 
(NSCLC). Of these, approximately 15-20% are 
diagnosed at an early stage [2]. With the increasing 
use of CT for lung cancer screening, there is an 
expected increase in the proportion of patients 
diagnosed with Stage I disease [3]. For operable 
candidates, surgery is the treatment of choice and 
yields 5-year overall survival rates of 60-70%. Primary 
radiation therapy utilizing stereotactic body radiation 
therapy (SBRT) has emerged as the curative intent 
approach for patients who are unable to undergo or 
who refuse surgery [4]. 
SBRT delivers a very high dose of radiation per 
fraction to a limited-sized target over a short period of 
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time. This technique has proven to be more effective 
than standard fractionation techniques for patients with 
early stage lung cancer with control rates of 90% and 
greater [5-12]. SBRT, however, requires a high degree 
of accuracy in treatment planning and delivery in order 
to achieve this degree of efficacy. SBRT treatments on 
a standard Linac can be delivered either utilizing an 
intensity-modulated radiotherapy (IMRT) technique or 
via volumetric-modulated arc therapy (VMAT). IMRT 
involves 5 or more fixed fields that can be varied only 
with respect to the position of the multileaf collimators 
while the beam is on. VMAT, on the other hand, allows 
for full gantry rotation around a 360 degree arc, with 
variation of the dose rate, speed of gantry angle 
rotation, and position of the multileaf collimators. VMAT 
offers several advantages over IMRT which include 
decreased number of monitor units, shorter treatment 
time, decreased skin dose, and a lower mean lung 
dose [13-15].  
While a promising treatment modality with proven 
efficacy in managing early stage lung cancer, delivery 
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of VMAT SBRT to lung lesions presents a number of 
dosimetric challenges due to the loss of lateral scatter 
equilibrium as the radiation beam crosses the tissue-air 
interface. Selecting the appropriate photon energy to 
use in treatment planning is one of these challenges. 
Studies have shown that using higher energy photon 
beams results in the under-dosing of tumors secondary 
to the loss of build-up as the beam enters the target 
from the low-density lung [16]. Loss of lateral scatter is 
even more pronounced with small field dosimetry, 
which is required for SBRT, further complicating the 
choice of beam energy. As a result, low energy beams 
in the range of 4-10MV have been recommended by 
national and international agencies [17] and are being 
used in prospectively designed trials [5, 6, 8, 10-12]. 
The disadvantage of using such low energies is inferior 
coverage of the entire target resulting from the poorer 
penetrating ability of the lower energy beam.  
The present study undertook to investigate whether 
there is an optimal energy within the lower range of 
energies used in radiation therapy that should be 
selected when using VMAT SBRT in the treatment of 
lung tumors. In particular, we compared dosimetric 
data for 6-MV versus 10-MV energies. We further 
sought to uncover subsets of patients in which 
selection of a particular energy would result in more 
optimal treatment plans. 
MATERIALS AND METHODS 
33 consecutive patients with a total of 35 lung 
lesions treated by VMAT SBRT at our institution were 
included in this study with IRB approval. All but one 
patient were treated for primary lung cancer. The 
remaining patient was treated for oligometastatic 
sarcoma after refusing other therapies.  
Each patient underwent computed tomographic 
(CT) simulation in the supine position using a 
BlueBAG™ BodyFIX Vacuum Cushion by Elekta. 4D-
CT scans were obtained for each patient to assess 
tumor motion throughout the breathing cycle. Each 
tumor was contoured on the planning CT which was 
then fused with the 4D-CT to create an internal target 
volume (ITV) in order to account for tumor motion 
during the respiratory cycle. A 3mm margin was then 
added to the ITV to create the planning target volume 
(PTV). Treatments were delivered in 3-5 daily fractions, 
with a median total dose of 5000cGy. All patients were 
treated with either 6MV or 10MV photon beams on a 
Varian Clinac iX Linear Accelerator. Daily cone-beam 
computed tomographic (CBCT) scans were taken to 
ensure patient set-up accuracy.  
Dosimetric plans using both 6-MV and 10-MV 
energies were generated for each lesion and all plans 
were identically optimized. Dose was calculated using 
Varian Eclipse AAA (Anisotropic Analytical Algorithm) 
convolution-superposition photon-beam dose compu- 
tation algorithm (version 8.6), with heterogeneity 
corrections applied. All plans utilized the VMAT 
technique and were coplanar. The organ at risk (OAR) 
constraints used for optimization were obtained from 
Radiation Therapy Oncology Group (RTOG) protocol 
0236. Dosimetric parameters including isocenter, 
number of arcs, and degree of arc rotation were 
identical for the 6-MV and 10-MV plans for each 
patient. Each plan was normalized such that 95% of 
the PTV received 100% of the prescribed dose. 
Dosimetric Parameters Used for Analysis 
Dose-volumetric parameters analyzed for 
comparison included the following: the maximum dose 
to the PTV (PTVmax), the maximum dose to the spinal 
cord (Cord Dmax), the mean dose to the sum lung, the 
lung V13, the conformity index (CI), the gradient 
measure (GM), integral dose, and the total number of 
monitor units (MUs). 
The PTVmax was defined as the highest dose 
within the PTV recorded as a percentage of the total 
dose. The closer the PTVmax to 100%, the more 
homogeneous the dose delivered to the target volume. 
The Cord Dmax was recorded as the highest dose in 
cGy anywhere within the cord. The sum lung included 
the volume of both lungs minus the Gross Tumor 
Volume (GTV). The mean dose to the sum lung was 
obtained from Eclipse as the average dose in cGy 
delivered to this structure. The lung V13 was defined 
as the volume of the sum lung receiving 13Gy or more. 
The lower the values of the Cord Dmax, the mean lung 
dose, and the lung V13, the more favorable the plan.  
The CI was calculated as the volume enclosed by 
the prescription isodose surface divided by the target 
volume. The closer the value to unity, the more optimal 
the plan, with a value less than one indicating 
underdosage of the PTV and a value greater than one 
indicating potential toxicity to surrounding healthy 
tissue. The GM was defined as the difference between 
the equivalent sphere radius of the prescription and the 
half-prescription isodoses with a smaller value 
indicating a sharper dose fall-off and, therefore, a more 
optimal plan [18]. Figure 1 shows the isodose curves 
including the 50% isodose lines for the 6-MV and 10-
MV plans generated for a patient with a peripheral 
tumor. The normal tissue integral dose was calculated 
as the product of the mean dose to the volume of the 
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body over the length of the PTV (excluding the PTV), 
and the volume of that region (again excluding the 
volume of the PTV), with units of Liter-Gray (L-Gy). The 
total number of MUs were also recorded for each plan 
with a smaller value indicating a more optimal plan 
given the shorter beam on time.  
Sub-Group Analysis 
The above parameters were compared for the 6-MV 
and 10-MV plans using 2-tailed sign tests for both the 
entire cohort and within certain subsets of patients. 
These subsets included patients stratified into two 
groups depending on tumor location, distance from the 
chest wall, anterior-posterior (AP) separation and 
patient diameter as shown in Table 1. 
Patients stratified by tumor location were divided 
into those with central tumors and peripheral tumors. 
Central tumors were defined as those lying within 2 cm 
in all directions around the proximal bronchial tree as 
delineated in RTOG 02365, while peripheral tumors 
were those not meeting this definition. Patients 
stratified by distance from the chest wall were divided 
into those with PTVs including a portion of or abutting 
the chest wall (0cm), and those that neither 
encompassed nor abutted the chest wall (>0cm).  
The AP separation was measured across the 
central axis of the patient at the isocenter. The median 
AP diameter for our cohort of patients was 22cm. 
Patients stratified according to this parameter were 
therefore divided into those with a separation less than 
or equal to 22 cm (≤22cm) and those with a separation 
greater than 22 cm (>22cm). Finally, patient diameter 
was defined as the diameter of an equivalent sphere 
encompassing the patient's body over the distance of 
the PTV. This parameter was chosen to serve as 
another means of measuring the volume of tissue 
being traversed by the radiation beams in reaching the 
target volume. It was included in addition to AP 
separation because in VMAT plans, as opposed to 
IMRT plans, radiation beams enter the patient from 
anywhere along a 360 degree arc. The volume of 
tissue traversed anywhere along this 360 degree arc is, 
therefore, of relevance. The median patient diameter 
for our group of patients was 18cm. Patients stratified 
according to the patient diameter were thus divided into 
those with an equivalent diameter less than or equal to 
18cm (≤18cm) or those with an equivalent diameter 
greater than 18cm (>18cm).  
Statistical Analysis 
Statistical analysis was performed using Microsoft 
Excel 2007 and STATA Statistical Software, version 
13.1. Two-sided T-tests were used to determine 
 
Figure 1: Axial and Saggital images of isodose curves for a patient with a peripheral lesion. The 95% ISL is shown in pink and 
the 50% is shown in white. Abbreviations: ISL, isodose level. 
 
Table 1: Number of Patients Within Each Subgroup 
 Tumor Location Distance from Chest Wall  AP Separation Peripheral Volume 
 Central Peripheral  0 cm > 0 cm ≤ 22cm > 22cm ≤ 18cm >18cm 
Number of Patients 9 26 10 25 18 17 18 17 
Abbreviations: AP, anterior-posterior. 
30    World Journal of Oncology Research, 2016, Vol. 3 Tchelebi et al. 
statistical significance. A p-value less than or equal to 
0.05 was considered statistically significant (SS).  
RESULTS 
There were no SS differences between the 6 MV 
and the 10 MV plans among any of the parameters 
tested, except for the mean lung dose and the total 
MUs. The difference in the mean lung dose favored the 
6-MV plans (194 cGy vs 201 cGy, p = 0.04), while the 
total number of MUs favored the 10-MV plans (2425 
MU vs 2213 MU, p<0.01). The mean, median, and 
range for the various parameters are shown in Table 
2A and 2B. The data for the overall cohort is shown in 
Table 3. 
Table 4 shows our results for lesions stratified 
according to location within the lung. Among patients 
with centrally located tumors, the only parameter that 
was SS was the total number of MUs, which favored 
the 10 MV plans (3180 MU vs 2166 MU, p=0.04). 
Among those with peripherally located tumors, the CI 
and the total number of MUs were SS different 
between the 6-MV and 10-MV plans. The CI favored 
the 6-MV plans (1.19 vs 1.23, p=0.04) , while the total 
number of MUs favored the 10-MV plans (2383 vs 
2245, p<0.01).  
Table 5 shows patients stratified according to the 
distance from the chest wall. The total number of MUs 
was the only variable showing a SS difference among 
those with PTVs with a distance of 0 cm from the chest 
wall and those with a PTV farther than 0 cm from the 
chest wall, again favoring the 10-MV plans (p<0.01). 
Stratification according to AP diameter is shown in 
Table 6. There was a SS difference in mean lung dose 
and total number of MUs for patients with a diameter 
less than or equal to 22 cm. Within this subset of 
patients, the mean lung dose favored the 6-MV plans 
(178 vs 189, p=0.01), while the total number of MUs 
favored the 10-MV plans (2425 vs 2276, p=0.02). For 
patients with a total separation greater than 22 cm, the 
Table 2a: Mean, Median, and Range for each Dosimetric Parameter for 6-MV Plans is shown in this Table 












Dose  Total MUs 
Mean 118 23 231 221 1.18 1.41 3.90 2892 
Median 116 20 216 194 1.16 1.44 3.73 2425 
Range 106-134 8-61 0-487 26-429 0.76-1.50 1.05-1.95 2.98-5.74 1596-6233 
Abbreviations: MV, mega-voltage; PTVmax, maximum dose to the planning target volume; Cord Dmax, maximum cord dose; Lung V13, 
volume of lung receiving at least 13Gy; MU, monitor units. 
 
Table 2b: Mean, Median, and Range for each Dosimetric Parameter for 10-MV Plans is shown in this Table 












(L-Gy) Total MUs 
Mean 118 25 235 228 1.24 1.49 4.06 2732 
Median 116 22 214 202 1.20 1.47 3.88 2213 
Range 102-195 7-66 0-479 24-471 0.76-1.50 1.09-2.27 2.96-5.79 1353-8626 
Abbreviations: MV, mega-voltage; PTVmax, maximum dose to the planning target volume; Cord Dmax, maximum cord dose; Lung V13, 
volume of lung receiving at least 13Gy; MU, monitor units. 
Table 3: Dose-Volumetric Comparison of the Mean 
Value of each Parameter for the 6-MV and 10-
MV Plans for the Cohort Overall. A p-value of 
0.05 or Less was Considered Significant and is 
Indicated with an Asterisk 
 Cohort Overall 
Energy (MV) 6-MV 10-MV p-value 
PTVmax (cGy) 116 116 0.31 
Cord Dmax (cGy) 20 22 0.61 
Lung V13 (cc) 216 214 0.30 
Mean Sum Lung 
Dose (cGy) 194 202 0.04* 
Conformity Index 1.16 1.2 0.06 
Gradient Measure 1.44 1.47 0.11 
Integral Dose (L-Gy) 3.73 3.88 0.99 
Total MUs 2425 2213 <0.01* 
Abbreviations: MV, mega-voltage; PTVmax, maximum dose to the 
planning target volume; Cord Dmax, maximum cord dose; Lung V13, 
volume of lung receiving at least 13Gy; MU, monitor units.  
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total number of MUs was different between the 6-MV 
and 10-MV plans, favoring 10-MV (2393 vs 2166, 
p<0.01).  
Table 4: Dose-Volumetric Comparison of the Mean Value of each Parameter for the 6-MV and 10-MV Plans in Patients 
Stratified by Location within the Lung, Central or Peripheral. A p-value of 0.05 or Less was Considered 
Significant and is Indicated with an Asterisk 
 Site 
Subgroup Central Peripheral 
Energy (MV) 6 10 p-value 6 10 p-value 
PTVmax (cGy) 120 117 0.99 116 115 0.33 
Cord Dmax (cGy) 27 23 0.18 19 20 0.99 
Lung V13 (cc) 242 237 0.73 190 200 0.42 
Mean Sum Lung Dose (cGy) 221 216 0.51 193 202 0.06 
Conformity Index 1.09 1.13 0.99 1.19 1.23 0.04* 
Gradient Measure 1.58 1.68 0.99 1.43 1.43 0.11 
Integral Dose (L-Gy) 4.12 4.32 0.73 3.73 3.77 0.85 
Total MUs 3180 2166 0.04* 2383 2245 < 0.01* 
 
Table 5: Dose-Volumetric Comparison of the Mean Value of each Parameter for the 6-MV and 10-MV Plans in Patients 
Stratified by Distance from the Chest Wall. A Value of 0cm Indicates that the Lesion was Abutting, or 
Including a Portion of, the Chest Wall. A p-value of 0.05 or Less was Considered Significant and is Indicated 
with an Asterisk 
 Distance from Chest Wall (cm) 
Subgroup 0 >0 
Energy (MV) 6 10 P- value 6 10 P- value 
PTVmax (cGy) 116 116 0.42 118 116 0.75 
Cord Dmax (cGy) 20 23 0.84 20 19 0.75 
Lung V13 (cc) 242 243 0.31 157 158 0.99 
Mean Sum Lung Dose (cGy) 221 202 0.09 158 185 0.34 
Conformity Index 1.16 1.2 0.15 1.15 1.18 0.34 
Gradient Measure 1.44 1.47 0.21 1.35 1.43 0.51 
Integral Dose (L-Gy) 3.72 3.70 0.42 4.07 4.48 0.18 
Total MUs 2425 2276 < 0.01* 2455 2067 0.02* 
 
Table 6: Dose-Volumetric Comparison of the Mean Value of each Parameter for the 6-MV and 10-MV Plans in Patients 
Stratified by AP Separation Measured in Centimeters. A p-value of 0.05 or Less was Considered Significant 
and is Indicated with an Asterisk 
 AP Separation (cm) 
Subgroup ≤22 >22 
Energy (MV) 6 10 P- value 6 10 P- value 
PTVmax (cGy) 119 116 0.99 116 115 0.26 
Cord Dmax (cGy) 20 22 0.99 20 22 0.50 
Lung V13 (cc) 169.8 180.1 0.3013 266.7 275.6 0.81 
Mean Sum Lung Dose (cGy) 178 189 0.01* 258 260 0.65 
Conformity Index 1.24 1.33 0.12 1.12 1.13 0.36 
Gradient Measure 1.41 1.39 0.12 1.44 1.49 0.63 
Integral Dose (L-Gy) 3.84 4.06 0.61 3.72 3.82 0.82 
Total MUs 2425 2276 0.01* 2393 2166 < 0.01* 
Abbreviations: AP, anterior-posterior. 
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As shown in Table 7, there were a number of 
parameters with SS differences between the 6-MV and 
the 10-MV plans among patients with a patient 
diameter less than or equal to 18 cm. The CI (1.23 vs 
1.3, p<0.01), mean lung dose (178 vs 192, p<0.01), 
and lung V13 (157 vs 173, p=0.05) all favored the 6-
MV plans. The total number of MUs, on the other hand, 
favored the 10-MV plans (2523 vs 2468, p<0.01). 
Among patients with a patient diameter greater than 
18cm, the only SS difference between the 6-MV and 
10-MV plans was in the total number of MUs, favoring 
the 10-MV plans (2354 vs 2147, p<0.01). 
DISCUSSION 
To our knowledge, this is the first study that 
analyzes the effect of beam energy on VMAT treatment 
planning within the low energy range currently 
recommended for use in lung SBRT. Previous studies 
have focused on the effect of using a high versus a low 
beam energy, primary 6-MV versus 18-MV, for the 
treatment of lung tumors using a variety of different 
treatment techniques, including 3D-conformal 
treatment planning and static IMRT [19-22]. Studies 
such as these contributed to the recommendation that 
low energy photon beams, ≤ 10-MV, be used in 
treatment planning for lung lesions. However, little is 
known about the optimal energy to use within this 
range and whether or not there are any parameters 
that would guide the selection of one energy over 
another. Specifically, data are lacking in the choice of 
energy selection in VMAT treatment planning where 
beamlets delivering the dose to the target are able to 
do so over a 360-degree arc, therefore traversing a 
distinct volume of body tissue and air.  
With the exception of the mean sum lung dose, 
which was slightly higher for 10-MV plans, planning 
with 6-MV did not prove to be superior for the cohort 
overall. This is in accordance with the findings of the 
study by Weiss et al, who compared planning with 6MV 
versus 18MV in lung IMRT and concluded that higher 
photon energies should not be excluded a priori in all 
patients [20]. The only subgroup of patients for which 
planning with 6-MV over 10-MV consistently showed a 
benefit in more than one parameter, and could thus be 
said to offer a more optimal plan, is among patients 
with a patient diameter less than or equal to 18cm. 
Among this group of patients, planning with the lower 
energy resulted in a lower mean sum lung dose, a 
lower lung V13, and a superior conformity index.  
10-MV plans, however, consistently demonstrated 
superiority with respect to the total number of monitor 
units needed to deliver the prescribed dose to the 
target volume. In fact, the difference in magnitude 
between the total number of MUs for 6-MV versus 10-
MV plans was close to ten percent for each subgroup, 
in favor of 10-MV. For any tumor that was not abutting 
or invading the chest wall, planning with 6-MV required 
twenty-percent more monitor units to deliver the same 
dose to the same target as compared to 10-MV. The 
difference in monitor units was especially pronounced 
for central lesions where the total number of MUs for 
the 10-MV plans was two-thirds that of the 6-MV plans.  
The total number of MUs is always expected to 
increase with decreasing energy and this increase 
should be taken into consideration when selecting the 
optimal treatment plan. The percent depth dose, PDD, 
increases at higher energies. Given that the total 
Table 7: Dose-Volumetric Comparison of the Mean Value of each Parameter for the 6-MV and 10-MV Plans in Patients 
Stratified by Peripheral Volume Measured in Cubic Centimeter. A p-value of 0.05 or Less was Considered 
Significant and is Indicated with an Asterisk 
 Patient Diameter (cm) 
Subgroup ≤18 >18 
Energy (MV) 6 10 P- value 6 10 P- value 
PTVmax (cGy) 119 117 0.24 116 115 0.99 
Cord Dmax (cGy) 18 20 0.99 22 24 0.33 
Lung V13 (cc) 157 173 0.05* 292 297 0.80 
Mean Sum Lung Dose (cGy) 178 192 <0.01* 301 297 0.99 
Conformity Index 1.23 1.30 <0.01* 1.13 1.11 0.99 
Gradient Measure 1.32 1.32 0.81 1.48 1.64 0.06 
Integral Dose (L-Gy) 3.95 3.94 0.63 3.68 3.88 0.63 
Total MUs 2523 2468 <0.01* 2354 2147 < 0.01* 
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number of MUs is equal to the dose divided by the 
product of the PDD (in addition to a number of other 
correction factors), we would expect the total number of 
MUs to decrease as the PDD increases [23]. 
Therefore, lower energy photon beams result in a 
higher number of MUs to deliver the same dose as 
compared to higher energy beams.  
Increasing the total number of monitor units results 
in a longer treatment time which, in turn, allows for 
greater intrafractional tumor motion. The movement of 
lung lesions during targeted radiation therapy has been 
well studied [24-28]. As suggested by Seppendwoolde 
et al, this motion is not strictly due to tumor motion 
resulting from the respiratory cycle, but is also driven 
by gravity, changes in muscle tone, and changes in 
patient position [28]. While the use of immobilization 
devices, intrafractional tumor tracking, and breath-hold 
techniques are all utilized to minimize tumor motion 
during treatment, some degree of motion is inevitable 
and is more likely to occur during a longer treatment. 
Indeed, in their study assessing the importance of 
CBCT for tumor localization during lung SBRT, Purdie 
et al note a significant change in tumor position with 
prolonged treatment sessions [29].  
Minimizing tumor motion is particularly important for 
SBRT treatments in which a very high dose is delivered 
in a small number of fractions to a small target volume. 
In their paper on the effects of intrafraction tumor 
motion on dosimetric data for lung SBRT, Zhao et al 
demonstrated a deviation of up to 14% in the dose 
delivered to 95% of the PTV even with the use of 
respiratory gating [30]. The addition of a margin to the 
GTV to create a PTV, or the creation of an ITV in cases 
where tumor tracking is not available, allows some 
room for error with respect to tumor motion. However, 
due to the very high dose per fraction and the 
sensitivity of adjacent healthy lung to radiation, this 
margin must be kept small, potentially allowing for 
underdosing of the tumor. In addition to the dosimetric 
consequences of a prolonged treatment time, a longer 
treatment is inconvenient for both the patient and the 
treating facility.  
Longer treatment times also results in longer beam 
on time. An increase in beam-on time results in 
increased leakage from the head of the machine and 
increased scatter from the collimators and flattening 
filter, which theoretically results in increased integral 
dose to the patient. Increased integral dose to the 
patient, in turn, may result in an increased risk of 
secondary malignancies as a result of therapeutic 
radiotherapy [31-33]. Our study, however, failed to 
show any differences in integral dose for 6-MV versus 
10-MV plans. This may be because of the averaging 
effect resulting from the dose being spread out among 
several beamlets as is the case in VMAT treatments.  
While selecting 10-MV for lung SBRT clearly results 
in fewer MUs and therefore shorter treatment times, 
there are disadvantages to selecting this energy over 
6-MV which should be considered. One of the 
consequences of using 10-MV is the production of 
neutrons, which are more biologically damaging than 
photons or electrons [34]. However, neutron 
contamination begins at 10-MV and is very low, or even 
negligible, at this photon energy [35]. Another 
disadvantage of 10-MV over 6-MV is in the increased 
uncertainty of the dose calculations at higher energies. 
This is especially true for calculations at tissue 
interfaces for small fields, as are used in lung SBRT 
[36]. With the exception of Monte Carlo, treatment 
planning algorithms are less accurate in those regions, 
resulting in a degree of uncertainty with respect to the 
dose delivered [37]. In order to reduce this uncertainty, 
small field dosimetry using scanning diodes was used 
during the commissioning tests of our Linac. 
While this study was retrospective and included a 
small sample size, it sheds some light on the ongoing 
debate regarding the optimal energy to use for lung 
VMAT SBRT where dose delivery to the target is 
challenging on account of the lung-tissue interface. 
CONCLUSION 
Our study shows that, with the exception of thinner 
patients with a diameter ≤ 18cm, for which 6-MV plans 
proved superior with respect to OARs and conformity 
index, 10-MV should be strongly considered for use in 
lung VMAT SBRT. We showed that plans using 10-MV 
had a statistically lower number of MUs as compared to 
6-MV plans which would result in a shorter treatment 
time, with the potential for improved target accuracy 
due to less intrafractional tumor motion.  
CONFLICT OF INTEREST 
The authors have no conflicts to disclose.  
ABBREVIATIONS  
OARs = Organs at Risk 
PTV = Planning Target Volume 
VMAT = Volumetric-Modulated Arc Therapy 
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SBRT = Stereotactic Body Radiation Therapy 
6-MV = 6-Megavoltage 
10-MV = 10-Megavoltage 
AP = Anterior-Posterior 
TCW = Tumor to Chest Wall distance 
ESD = Equivalent Sphere Diameter 
CI = Conformity Index 
SS = Statistically Significant 
Lung V13 = Volume of Lung receiving at least 13Gy 
MU = Monitor Unit 
NSCLC = Non-Small Cell Lung Cancer 
MRT = Intensity Modulated Radiation Therapy 
CT = Computerized Tomography 
ITV = Internal Target Volume 
GTV = Gross Tumor Volume 
CBCT = Cone-Beam Computerized Tomography 
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